NewsBabel NewsBabel

Global headlines in real time

1 Items
Active filters Topic: Makes Clear all

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

Tmt Newswire
24 Sep 2026, 12:11 GMT GlobeNewswire

2026 R&D Day presentation highlights include:

Download options
The Manila Times logo
Article IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
Credit: GlobeNewswire